MD1003-AMN MD1003 in Adrenomyeloneuropathy
Mots clés
Abstrait
La description
AMN and progressive multiple sclerosis share some similarities including progressive spastic paraparesis and secondary energy failure leading to progressive axonal degeneration. Therefore, it was hypothesized that high doses of biotin might be efficient in patients with AMN.
Rendez-vous
| Dernière vérification: | 10/31/2016 |
| Première soumission: | 11/08/2016 |
| Inscription estimée soumise: | 11/09/2016 |
| Première publication: | 11/10/2016 |
| Dernière mise à jour soumise: | 10/05/2017 |
| Dernière mise à jour publiée: | 10/08/2017 |
| Date de début réelle de l'étude: | 09/30/2014 |
| Date d'achèvement primaire estimée: | 05/31/2016 |
| Date estimée d'achèvement de l'étude: | 05/31/2017 |
Condition ou maladie
Intervention / traitement
Drug: MD1003 100 mg capsule
Drug: Placebo
Phase
Groupes d'armes
| Bras | Intervention / traitement |
|---|---|
| Experimental: MD1003 MD1003 100mg capsules, 1 capsule tid for 24 months | |
| Placebo Comparator: Placebo Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months | Drug: Placebo |
Critère d'éligibilité
| Âges éligibles aux études | 18 Years À 18 Years |
| Sexes éligibles à l'étude | Male |
| Accepte les bénévoles en santé | Oui |
| Critères | Inclusion Criteria: - ABCD1 gene mutation identified - Elevated plasma VLCFA - Clinical signs of AMN with at least pyramidal signs in the lower limbs and difficulties to walk - EDSS score ≥ 3.5 and ≤ 6.5 - Normal brain MRI or brain MRI showing : - abnormalities that can be observed in AMN patients without cerebral demyelination with a maximum Loes score of 4 - and/or stable (≥6 months) cerebral demyelination without gadolinium enhancement with a Loes score ≤12. - Appropriate steroid replacement if adrenal insufficiency is present - Likely to be able to participate in all scheduled evaluation visits and complete all required study procedures - Signed and dated written informed consent to participate in the study in accordance with local regulations - Affiliated to a Health Insurance Exclusion Criteria: - Brain MRI abnormalities with a Loes score > 12 or with gadolinium enhancement - Any progressive neurological disease other than AMN - Impossibility to perform the walk tests and the TUG test - Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or any progressive malignancy - Any new medication for AMN including Fampridine initiated less than 1 month prior to inclusion - Contra-indications for MRI procedure such as subjects with paramagnetic materials in the body, such as aneurysm clips, pacemakers, intraocular metal or cochlear implants. - Inclusion in another therapeutic clinical trial for ALD - Not easily contactable by the investigator in case of emergency or not capable to call the investigator |
Résultat
Mesures des résultats primaires
1. Mean change of 2 minutes walking test (2MWT) between Months 12 and baseline [Baseline and 12 Months]
Mesures des résultats secondaires
1. Proportion of patients with improved 2-Minutes-Walk-Tests (2MWT) of at least 20% [Baseline, 9 months, 12 months]
2. Proportion of patients with improved TW25 (time to walk 25 feet) of at least 20% [Baseline, 9 months, 12 months]
3. Mean Change in TW25 (time to walk 25 feet) [Baseline and 12 months]
4. Timed up and Go test (TUG) [12 Months]
5. Euroqol EQ-5D questionnaire [12 months]
6. Qualiveen Questionnaire [12 Months]
